Answer
Gastrointestinal perforation, including fatal cases, has been reported during Giotrif (afatinib dimaleate) treatment in 0.2% of patients across all randomized controlled clinical trials; treatment should be permanently discontinued if it occurs.
Sources for this answer
- Giotrif 20 mg film-coated tabletsBoehringer Ingelheim Limited · emc · SmPC §4.4 Special warnings and precautions for use · Version 1Document updated
Sources checked